{"@id":"https://bioecon.ru/technology/gene-therapy-for-phagocyte-disorders/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/gene-therapy-for-phagocyte-disorders/","json":"https://en.bioecon.ru/api/v1/technology/gene-therapy-for-phagocyte-disorders/index.json"},"id":"gene-therapy-for-phagocyte-disorders","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/shandong-shunfeng-biotechnology/","https://bioecon.ru/companies/hangzhou-ruifeng/","https://bioecon.ru/companies/origin-agritech/","https://bioecon.ru/companies/inari-agriculture/"]},"maturity":7,"name":"Gene Therapy for Phagocyte Disorders","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Mobilization and CD34+ harvesting"},{"n":2,"title":"Lentiviral vector integration"},{"n":3,"title":"Oxidative burst reconstitution"},{"n":4,"title":"Myeloablative autologous engraftment"}],"summary":"Ex-vivo autologous hematopoietic stem and progenitor cell (HSPC) gene addition and base editing restoring functional NADPH oxidase activity in mature neutrophils and macrophages, curing chronic granulomatous disease (CGD) and severe congenital phagocytopathies.","url":"/technology/gene-therapy-for-phagocyte-disorders/","verified":"2026-11-22"}